A monolithic semiconductor substrate

Chip Design Journal

Subscribe to Chip Design Journal: eMailAlertsEmail Alerts newslettersWeekly Newsletters
Get Chip Design Journal: homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn

Chip Design Authors: Jnan Dash, Jason Bloomberg, Trevor Bradley, David Strom

Related Topics: iPhone Developer, Chip Design

News Feed Item

ARM Holdings Analyst Coverage Initiated; iPhone 6 Parts Supplier is Subject to Analyst Report by Small Cap Street and BrokerBank Securities, Inc.

NEW YORK, Sept. 24, 2014 /PRNewswire/ -- Apple's new iPhone 6 and iPhone 6 Plus use a variety of components from numerous suppliers around the world. Winning a contract with Apple to supply even just one component in their widely-popular iPhones can be extremely lucrative for some companies. According to comScore data, even though Google's Android operating system dominates in market share, Apple's iPhone is the No. 1 device in the United States capturing approximately 42% of the market. One such company that Apple continues to use in their iPhones is ARM Holdings plc (ARMH), whose chip design runs the iPhone 6 and 6 Plus A8 processor.

ARM Holdings plc (NASDAQ: ARMH) designs microprocessors, physical intellectual property (IP), and related technology and software. The company also sells development tools that enhance the performance, cost-effectiveness and energy efficiency of high-volume embedded applications.

ARM licenses and sells its technology and products to leading international electronics companies, who manufacture, market and sell microprocessors, application-specific integrated circuits, application-specific standard processors, and microcontrollers for incorporation into a wide variety of end products. These products range from smartphones and tablets to digital televisions and PC peripherals. 

An in-depth analyst report on ARMH that includes competitive analysis, financial statement analysis, valuation discussion, technical analysis, analyst summary, and recommendation can be viewed by using the following link at no cost:


Copy and paste may be required.

About Small Cap Street

Once you read our reports written by our team of financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties at no cost.

Our Financial Analysts spend countless hours researching stocks. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges. These reports include a straightforward assessment of the company by a financial analyst who has pledged to remain free of influence when writing research reports.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis by Michael Maggi, a CFA charterholder. An outsourced research services provider represented by Michael Maggi, CFA, provided Small Cap Street this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Small Cap Street is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Michael Maggi, CFA. The subject Company has not compensated Small Cap Street or Michael Maggi for the creation or dissemination of this report. Michael Maggi, Chartered Financial Analyst, is the author of research report.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries, please contact us at [email protected].


Small Cap Street and BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Small Cap Street and BrokerBank Securities, Inc. are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. Small Cap Street has compensated Michael Maggi, CFA, for the right to disseminate analyst report. No liability is accepted by Small Cap Street and BrokerBank Securities, Inc. whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Street expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Street and BrokerBank Securities, Inc. do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.           

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.                                     

SOURCE Small Cap Street

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.